Droplet Size and Distribution of Nebulized 3% Sodium Chloride, Albuterol, and Epoprostenol by Phase Doppler Particle Analyzer.

Epoprostenol Flolan Inhalation devices Nebulizer Particle size

Journal

Current therapeutic research, clinical and experimental
ISSN: 0011-393X
Titre abrégé: Curr Ther Res Clin Exp
Pays: United States
ID NLM: 0372621

Informations de publication

Date de publication:
2021
Historique:
received: 03 11 2020
accepted: 11 02 2021
entrez: 26 7 2021
pubmed: 27 7 2021
medline: 27 7 2021
Statut: epublish

Résumé

Aerosolized drug therapy administered to mechanically ventilated patients is a standard part of pulmonary critical care medicine. Aerosol particle size and distribution are important factors in the optimal delivery of aerosolized drugs to ventilated patients. The objective of this study was to characterize aerosol droplet size and distribution with laser diffraction for nebulized 3% sodium chloride, albuterol, and epoprostenol sodium (containing glycine) delivered via Aeroneb Solo Mesh Nebulizers (Aerogen, Mountain View, California). A series of functional flow tests were run on each of 8 Solo mesh nebulizers before the study to verify accuracy of flow rates in milliliters per minute. Aerosolized droplets exiting the nebulizer heads were then measured using a phase Doppler particle analyzer. Data collected during delivery of 3% sodium chloride, albuterol, and epoprostenol sodium included aerosol droplet size distribution, mass median aerodynamic diameter (MMAD), and geometric standard deviation. For each Solo nebulizer, droplet size measurements were taken 2 cm away from the nebulizer head and 2 cm away from the wye of a heated, humidified adult ventilator circuit. For measurements taken at the wye, 4 distinct, continuous flow rates (2, 10, 20, and 40 L/min) were generated by an air pump to simulate inspiratory flows delivered with mechanical ventilation. The expiratory limb was capped, and the nebulizer head was inserted into the breathing circuit upstream of the humidifier. Each Solo nebulizer met Aerogen's recommended minimum flow rate of 0.2 mL/min, ranging from 0.23 to 0.31 mL/min. The MMAD of the 3 tested aerosols was several times smaller when measured at the wye outlet of the heated/humidified breathing circuit (0.82-2.73 µm) compared with droplets measured directly at the nebulizer outlet (MMAD, 4.6-7.3 µm). There was also significant variability across Solo heads with some ventilator flow rates. The mean MMAD at the wye for the 3% sodium chloride solution, albuterol, and epoprostenol test solutions was 1.62 µm, 1.09 µm, and 1.18 µm, respectively. The mean MMAD at the nebulizer for the 3% sodium chloride solution, albuterol, and epoprostenol test solutions was 5.37 µm, 5.73 µm, and 6.73 µm, respectively. Results from this study suggest that particle size of aerosolized drugs administered via a commonly used setup for delivery of in-line aerosols to mechanically ventilated patients may be several times smaller than expected and may result in less drug being delivered to the patient than previously realized.(

Sections du résumé

BACKGROUND BACKGROUND
Aerosolized drug therapy administered to mechanically ventilated patients is a standard part of pulmonary critical care medicine. Aerosol particle size and distribution are important factors in the optimal delivery of aerosolized drugs to ventilated patients.
OBJECTIVE OBJECTIVE
The objective of this study was to characterize aerosol droplet size and distribution with laser diffraction for nebulized 3% sodium chloride, albuterol, and epoprostenol sodium (containing glycine) delivered via Aeroneb Solo Mesh Nebulizers (Aerogen, Mountain View, California).
METHODS METHODS
A series of functional flow tests were run on each of 8 Solo mesh nebulizers before the study to verify accuracy of flow rates in milliliters per minute. Aerosolized droplets exiting the nebulizer heads were then measured using a phase Doppler particle analyzer. Data collected during delivery of 3% sodium chloride, albuterol, and epoprostenol sodium included aerosol droplet size distribution, mass median aerodynamic diameter (MMAD), and geometric standard deviation. For each Solo nebulizer, droplet size measurements were taken 2 cm away from the nebulizer head and 2 cm away from the wye of a heated, humidified adult ventilator circuit. For measurements taken at the wye, 4 distinct, continuous flow rates (2, 10, 20, and 40 L/min) were generated by an air pump to simulate inspiratory flows delivered with mechanical ventilation. The expiratory limb was capped, and the nebulizer head was inserted into the breathing circuit upstream of the humidifier.
RESULTS RESULTS
Each Solo nebulizer met Aerogen's recommended minimum flow rate of 0.2 mL/min, ranging from 0.23 to 0.31 mL/min. The MMAD of the 3 tested aerosols was several times smaller when measured at the wye outlet of the heated/humidified breathing circuit (0.82-2.73 µm) compared with droplets measured directly at the nebulizer outlet (MMAD, 4.6-7.3 µm). There was also significant variability across Solo heads with some ventilator flow rates. The mean MMAD at the wye for the 3% sodium chloride solution, albuterol, and epoprostenol test solutions was 1.62 µm, 1.09 µm, and 1.18 µm, respectively. The mean MMAD at the nebulizer for the 3% sodium chloride solution, albuterol, and epoprostenol test solutions was 5.37 µm, 5.73 µm, and 6.73 µm, respectively.
CONCLUSIONS CONCLUSIONS
Results from this study suggest that particle size of aerosolized drugs administered via a commonly used setup for delivery of in-line aerosols to mechanically ventilated patients may be several times smaller than expected and may result in less drug being delivered to the patient than previously realized.(

Identifiants

pubmed: 34306263
doi: 10.1016/j.curtheres.2021.100623
pii: S0011-393X(21)00001-1
pmc: PMC8296146
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100623

Informations de copyright

© 2021 The Authors.

Déclaration de conflit d'intérêts

This analysis was funded by Mallinckrodt Pharmaceuticals. The sponsor participated in the study design and in collection, assembly, analysis, and interpretation of data and participated in manuscript preparation, review, revisions, and final approval. K. McDermott received honoraria in 2017 as a participant for Mallinckrodt user manual validation testing. The authors have indicated that they have no other conflicts of interest regarding the content of this article.

Références

Ann Intensive Care. 2017 Dec;7(1):78
pubmed: 28766281
J Thorac Cardiovasc Surg. 2004 Apr;127(4):1058-67
pubmed: 15052203
J Allergy Clin Immunol. 2003 Jul;112(1):58-63
pubmed: 12847480
Anesthesiology. 2017 Aug;127(2):383
pubmed: 28323647
Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1985-7
pubmed: 8665066
Allergy Asthma Proc. 2010 Sep-Oct;31(5):85-90
pubmed: 20929599
Respir Care. 2017 Oct;62(10):1343-1367
pubmed: 28874611
Respir Care. 2015 Jun;60(6):858-74; discussion 874-9
pubmed: 26070580
Lancet. 1995 Jul 1;346(8966):51-2
pubmed: 7603160
AAPS J. 2004 Aug 22;6(3):e20
pubmed: 15760105
Anesthesiology. 2004 Apr;100(4):1023-5
pubmed: 15087645
Ther Deliv. 2018 Feb;9(2):121-136
pubmed: 29325508
AAPS PharmSciTech. 2013 Mar;14(1):375-90
pubmed: 23344853
J Aerosol Med Pulm Drug Deliv. 2012 Jun;25(3):140-7
pubmed: 22686623
Respir Care. 2015 Jan;60(1):38-46
pubmed: 25516995
J Aerosol Med Pulm Drug Deliv. 2016 Apr;29(2):134-41
pubmed: 26196740
Respir Care. 2015 Jun;60(6):794-802; discussion 802-5
pubmed: 26070575
Respir Care. 2010 Jul;55(7):845-51
pubmed: 20587095
Med Devices (Auckl). 2016 Apr 12;9:45-51
pubmed: 27110141
Nat Rev Drug Discov. 2007 Jan;6(1):67-74
pubmed: 17195033

Auteurs

Kelly McDermott (K)

University of Wisconsin Hospitals and Clinics, Madison, Wisconsin.

Jason G Oakley (JG)

Department of Mechanical Engineering, University of Wisconsin-Madison College of Engineering, Madison, Wisconsin.

Classifications MeSH